Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.
Maria-Victoria Mateos-MantecaJoaquin Martinez LopezPaula Rodriguez OteroVerónica González-CalleMarta Sonia GonzalezAlbert OrtiolNorma C GutiérrezRafael Rios-TamayoLaura RosinolMiguel Angel Alvarez RivasJoan BargayAna Pilar Gonzalez-RodriguezAdrian AlegreFernando EscalanteMaría Belén Iñigo RodríguezJavier de la RubiaAna Isabel TeruelFelipe De ArribaLuis PalomeraMiguel-Teodoro T Hernandez GarciaJavier López JiménezMarta Reinoso-SeguraAránzazu García MateoEnrique María OcioJuan José LahuertaNoemi PuigMaría-Teresa CedenaJoan BladéJuan-José LahuertaJesús San F Miguelnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Although a longer follow-up is needed, this curative approach is encouraging and more effective than active MM, with 31% of the patients maintaining the uMRD 4 years after HDM-ASCT.